FIELD: biochemistry.
SUBSTANCE: invention relates to an antibody which specifically binds to PD-1. Also disclosed is a composition comprising said antibody, a polynucleotide encoding said antibody, a vector and a host cell containing said polynucleotide. Disclosed are methods of treating cancer and infectious diseases associated with PD-1, reducing a tumor associated with PD-1, a method for increasing T-cell activation.
EFFECT: invention provides effective treatment of diseases associated with PD-1.
42 cl, 19 dwg, 8 ex, 16 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| ANTIBODIES AGAINST PROGRAMMED CELL DEATH LIGAND 1 AND THEIR USE | 2020 |
|
RU2786235C1 |
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
